Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04680429 · ClinicalTrials.gov registry record · Phase 1
A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects
A Phase 1 study, sponsored by Rhizen Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT04680429 is a Phase 1 study that has completed, run by Rhizen Pharmaceuticals. The registered enrollment target is 42 participants.
The verdict
NCT04680429, a Phase 1 study, has completed, sponsored by Rhizen Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a randomized, double-blind study to evaluate the safety, tolerability and PK of single and multiple ascending oral doses of RP7214. The relative bioavailability in fed and fasting conditions will also be evaluated for RP7214. The study comprises three parts; Part 1: Single ascending dose, Part 2: Multiple ascending dose and Part 3: Food effect.
Interventions
- DRUG Placebo
- DRUG RP7214
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-12-29 |
| Est. Completion | 2021-07-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04680429
The ClinicalTrials.gov registry entry for NCT04680429 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhizen Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04680429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04680429 about?
NCT04680429 is a clinical study titled "A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects". This is a randomized, double-blind study to evaluate the safety, tolerability and PK of single and multiple ascending oral doses of RP7214. The relative bioavailability in fed and fasting conditions will also be evaluated for RP7214. The study comprises three parts; Part 1: Single ascending dose, Pa...
What is the current status of trial NCT04680429?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2020-12-29. Estimated completion is 2021-07-19.
What interventions are being tested in trial NCT04680429?
The interventions under investigation include: Placebo (DRUG), RP7214 (DRUG).
Who is sponsoring clinical trial NCT04680429?
This trial is sponsored by Rhizen Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.